Key Benefits

BRONCHICINE CAe is licensed for the vaccination of healthy dogs 8 weeks of age or older as an aid in the control of canine infectious tracheobronchitis (kennel cough) caused by Bordetella bronchiseptica.

BRONCHICINE CAe is a killed cellular antigen extract of the Bordetella bronchiseptica microorganism.

BRONCHICINE CAe is prepared from antigenic material extracted from B. bronchiseptica. An immunogenic strain of B. bronchiseptica is grown to a high yield, then subjected to a proprietary process that extracts the antigens from the B. bronchiseptica cells. The residual cell debris is then removed, resulting in a product that retains the desirable immunologic qualities of a whole cell vaccine, while helping reduce undesirable adverse events (AEs).


BRONCHICINE CAe has sold more doses than any other parenteral B. bronchiseptica vaccine for dogs.1

Bordetella pertussis and B. bronchiseptica are closely related.2

The presence of vaccine-induced serum antibodies is a good correlate of immunity against B. pertussis in children3 and against B. bronchiseptica in dogs.4

Parenterally administered BRONCHICINE CAe vaccine has been demonstrated to have a low rate of AEs associated with administration.

Animal Bites

82% of veterinary workers’ compensation claims are from animal bites and scratches.*,5

BRONCHICINE CAe is administered further from the mouth.

Protection beyond the vaccine

The Zoetis Petcare Immunization Support Guarantee:

Covers diagnostics to establish whether a pet vaccinated with one of the Zoetis vaccine antigens has contracted the corresponding disease.

If the diagnostics confirm the corresponding disease, the Petcare Immunization Support Guaranteee will cover physical examination, ancillary diagnostic and therapeutic charges up to a maximum of $5,000.

Includes coverage for up to four years on core antigens and up to one year on most non-core antigens.

Dosage & Administration

Directions: Shake well. Aseptically administer 1 mL subcutaneously. Healthy dogs should receive 2 doses administered 2-4 weeks apart. Annual revaccination with a single dose is recommended.

The effect of persisting B. bronchiseptica maternal antibody on the immune response in puppies to the bacterin has not been determined. Puppies from bitches immune to the organism usually have low antibody titers that are dissipated by 4-6 weeks of age. Although kennel cough is considered a disease of complex etiology, it can be reproduced by challenge with B. bronchiseptica alone. A close association and/or confinement of dogs facilitates spread of the disease syndrome. Antibiotic therapy has been shown to be generally unsuccessful in reducing or eliminating B. bronchiseptica in dogs.


Store at 2°-7°C (35°-45°F). Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this vaccine. Transient local irritation at the site of injection, though rare, may occur subsequent to use of this product. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

Technical inquiries should be directed to Zoetis Veterinary Services,
1-888-Zoetis1 (1-888-963-8471) (USA).

* Date range: 1/1/07 to 6/30/11.

All pet care vaccines are covered with the exception of all Defensor® and Felocell® FIP products.

1.Animalytix data has not shown a competitive injectable Bordetella brochiseptica vaccine 2012 through January, 2018.

2. Parkhill J, Sebaihia M, Preston A, et al. Comparative analysis of genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet. 2003;35(1):32-40.

3. Cherry JD, Gombein J, Heinginger U, Stehr K. A search of serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16(20):1901-1906.

4. Ellis JA, Hanes DM, West KH, et al. Effect of vaccination on experimental infection with Bordetella bronchiseptica in dogs. JAVMA. 2001;218(3):367-375.

5. AVMA PLIT lists top claims for business insurance [JAVMA News]. October 15, 2012. Available at: Accessed February 27, 2018.